share_log

Avalo Therapeutics | 8-K/A: Current report (Amendment)

Avalo Therapeutics | 8-K/A: Current report (Amendment)

Avalo Therapeutics | 8-K/A：重大事件(修正)
美股sec公告 ·  06/24 16:06
Moomoo AI 已提取核心信息
Avalo Therapeutics, Inc. has filed an amendment to its Form 8-K, originally submitted on March 28, 2024, to include restated financial statements for AlmataBio, Inc. for the year ending December 31, 2023. The amendment, filed on June 24, 2024, addresses a misstatement in AlmataBio's operating expenses. Avalo had completed the acquisition of AlmataBio on March 27, 2024, and the restated financials reflect adjustments to research and development expenses and general and administrative expenses. The restatement increased AlmataBio's net loss by $153,000 for the year. Avalo's acquisition of AlmataBio was a stock-for-stock transaction, with AlmataBio's equity exchanged for Avalo common stock and non-voting convertible preferred stock. The transaction also included a $7.5 million cash payment to AlmataBio stockholders and potential future milestone payments.
Avalo Therapeutics, Inc. has filed an amendment to its Form 8-K, originally submitted on March 28, 2024, to include restated financial statements for AlmataBio, Inc. for the year ending December 31, 2023. The amendment, filed on June 24, 2024, addresses a misstatement in AlmataBio's operating expenses. Avalo had completed the acquisition of AlmataBio on March 27, 2024, and the restated financials reflect adjustments to research and development expenses and general and administrative expenses. The restatement increased AlmataBio's net loss by $153,000 for the year. Avalo's acquisition of AlmataBio was a stock-for-stock transaction, with AlmataBio's equity exchanged for Avalo common stock and non-voting convertible preferred stock. The transaction also included a $7.5 million cash payment to AlmataBio stockholders and potential future milestone payments.
Avalo Therapeutics，Inc.已经对其于2024年3月28日提交的8-K表格进行了修正，并于2024年6月24日提交了附加报告，以包括AlmataBio，Inc. 2023年12月31日的重申财务报表。该修正涉及对AlmataBio营业费用的误报。 Avalo于2024年3月27日完成收购AlmataBio，重申的财务报表反映了对研发费用和一般管理费用的调整。此财务重申使AlmataBio年度净亏损增加了153,000美元。Avalo对AlmataBio的收购是一项股票交易，其中AlmataBio的股权已交换为Avalo普通股和非表决可转换优先股。交易还包括向AlmataBio股东支付750万美元的现金和潜在的未来里程碑付款。
Avalo Therapeutics，Inc.已经对其于2024年3月28日提交的8-K表格进行了修正，并于2024年6月24日提交了附加报告，以包括AlmataBio，Inc. 2023年12月31日的重申财务报表。该修正涉及对AlmataBio营业费用的误报。 Avalo于2024年3月27日完成收购AlmataBio，重申的财务报表反映了对研发费用和一般管理费用的调整。此财务重申使AlmataBio年度净亏损增加了153,000美元。Avalo对AlmataBio的收购是一项股票交易，其中AlmataBio的股权已交换为Avalo普通股和非表决可转换优先股。交易还包括向AlmataBio股东支付750万美元的现金和潜在的未来里程碑付款。
有用
没用

该公告为独立文件：

独立文件1

独立文件2

独立文件3

独立文件4

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息